These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Targeting the Mycobacterium ulcerans cytochrome bc Scherr N; Bieri R; Thomas SS; Chauffour A; Kalia NP; Schneide P; Ruf MT; Lamelas A; Manimekalai MSS; Grüber G; Ishii N; Suzuki K; Tanner M; Moraski GC; Miller MJ; Witschel M; Jarlier V; Pluschke G; Pethe K Nat Commun; 2018 Dec; 9(1):5370. PubMed ID: 30560872 [TBL] [Abstract][Full Text] [Related]
4. Impact of Dose, Duration, and Immune Status on Efficacy of Ultrashort Telacebec Regimens in Mouse Models of Buruli Ulcer. Komm O; Almeida DV; Converse PJ; Omansen TF; Nuermberger EL Antimicrob Agents Chemother; 2021 Oct; 65(11):e0141821. PubMed ID: 34460302 [TBL] [Abstract][Full Text] [Related]
5. Repurposing of Tuberculosis Drug Candidates for the Treatment of Mycobacterium ulcerans Disease. Warryn L; Pluschke G Chimia (Aarau); 2023 Sep; 77(9):577-581. PubMed ID: 38047833 [TBL] [Abstract][Full Text] [Related]
6. Telacebec for Ultrashort Treatment of Buruli Ulcer in a Mouse Model. Almeida DV; Converse PJ; Omansen TF; Tyagi S; Tasneen R; Kim J; Nuermberger EL Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32205344 [TBL] [Abstract][Full Text] [Related]
7. Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses. Chauffour A; Robert J; Veziris N; Aubry A; Pethe K; Jarlier V PLoS Negl Trop Dis; 2020 Aug; 14(8):e0007857. PubMed ID: 32866170 [TBL] [Abstract][Full Text] [Related]
8. Determination of Bioenergetic Parameters in Mycobacterium ulcerans. Thomas SS; Pethe K Methods Mol Biol; 2022; 2387():219-230. PubMed ID: 34643916 [TBL] [Abstract][Full Text] [Related]
9. Dual inhibition of the terminal oxidases eradicates antibiotic-tolerant Mycobacterium tuberculosis. Lee BS; Hards K; Engelhart CA; Hasenoehrl EJ; Kalia NP; Mackenzie JS; Sviriaeva E; Chong SMS; Manimekalai MSS; Koh VH; Chan J; Xu J; Alonso S; Miller MJ; Steyn AJC; Grüber G; Schnappinger D; Berney M; Cook GM; Moraski GC; Pethe K EMBO Mol Med; 2021 Jan; 13(1):e13207. PubMed ID: 33283973 [TBL] [Abstract][Full Text] [Related]
10. Unlocking Opportunities for Shyam M; Kumar S; Singh V ACS Infect Dis; 2024 Feb; 10(2):251-269. PubMed ID: 38295025 [TBL] [Abstract][Full Text] [Related]
11. Drug Efficacy Testing in the Mouse Footpad Model of Buruli Ulcer. Converse PJ; Almeida DV; Nuermberger EL Methods Mol Biol; 2022; 2387():195-207. PubMed ID: 34643914 [TBL] [Abstract][Full Text] [Related]
12. High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease. Omansen TF; Almeida D; Converse PJ; Li SY; Lee J; Stienstra Y; van der Werf T; Grosset JH; Nuermberger EL Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30455239 [TBL] [Abstract][Full Text] [Related]
13. Molecular Informatics Studies of the Iron-Dependent Regulator (ideR) Reveal Potential Novel Anti- Kwofie SK; Enninful KS; Yussif JA; Asante LA; Adjei M; Kan-Dapaah K; Tiburu EK; Mensah WA; Miller WA; Mosi L; Wilson MD Molecules; 2019 Jun; 24(12):. PubMed ID: 31234337 [TBL] [Abstract][Full Text] [Related]
14. Mycobacterium ulcerans Population Genomics To Inform on the Spread of Buruli Ulcer across Central Africa. Vandelannoote K; Phanzu DM; Kibadi K; Eddyani M; Meehan CJ; Jordaens K; Leirs H; Portaels F; Stinear TP; Harris SR; de Jong BC mSphere; 2019 Feb; 4(1):. PubMed ID: 30728280 [TBL] [Abstract][Full Text] [Related]
15. Exploiting the synthetic lethality between terminal respiratory oxidases to kill Kalia NP; Hasenoehrl EJ; Ab Rahman NB; Koh VH; Ang MLT; Sajorda DR; Hards K; Grüber G; Alonso S; Cook GM; Berney M; Pethe K Proc Natl Acad Sci U S A; 2017 Jul; 114(28):7426-7431. PubMed ID: 28652330 [TBL] [Abstract][Full Text] [Related]
16. The compound TB47 is highly bactericidal against Mycobacterium ulcerans in a Buruli ulcer mouse model. Liu Y; Gao Y; Liu J; Tan Y; Liu Z; Chhotaray C; Jiang H; Lu Z; Chiwala G; Wang S; Makafe G; Islam MM; Hameed HMA; Cai X; Wang C; Li X; Tan S; Zhang T Nat Commun; 2019 Jan; 10(1):524. PubMed ID: 30705268 [TBL] [Abstract][Full Text] [Related]
17. In vitro antibacterial activity and in vivo efficacy of hydrated clays on Mycobacterium ulcerans growth. Adusumilli S; Haydel SE BMC Complement Altern Med; 2016 Jan; 16():40. PubMed ID: 26833071 [TBL] [Abstract][Full Text] [Related]